More questions over weight loss pharmacotherapy
The best treatment option for obesity is still up in the air, after researchers found patients had problems tolerating a key pharmacotherapy treatment option.
A combination weight loss treatment of phentermine and topiramate has recently been approved for use in the US, but more than half the patients in an Australian trial stopped taking the therapy due to adverse effects.
Of 103 patients dispensed the combination therapy, 61 ceased its use before then end of data collection. This was attributed to adverse events in 41 of these cases – including paraesthesia,